The Claim
In statin-intolerant patients, bempedoic acid reduces the risk of nonfatal myocardial infarction by 23% compared to placebo, with a hazard ratio of 0.77.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people who cannot tolerate statins, taking bempedoic acid lowers the chance of having a nonfatal heart attack by 23% compared to taking a placebo.
See the scientific wording
In statin-intolerant patients, bempedoic acid reduces the risk of nonfatal myocardial infarction by 23% (hazard ratio 0.77) compared to placebo, indicating a specific and clinically meaningful benefit in preventing heart attacks in this population.
A pill blocks a liver enzyme that makes cholesterol, causing the liver to pull more bad cholesterol out of the blood. Less cholesterol in the blood means less buildup in artery walls and less swelling in blood vessels, which prevents heart attacks.
What the research says
1 studyStudy: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
For people who can't take statins, this study found that taking bempedoic acid pills lowered their chance of having a heart attack by 23% compared to taking a sugar pill. It worked as claimed.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.